INVESTIGATING SECONDARY EFFECTS OF BACE1 INHIBITION, A PROMISING THERAPY FOR ALZHEIMER'S DISEASE
Grant number: 1058672 | Funding period: 2014 - 2016
Synapses transfer information between neurons in the brain. In Alzheimer’s disease (AD), synapse loss results in dementia therefore it is imperative that any potential therapeutic drugs do not inadvertently cause further synapse loss. Drugs aimed at blocking production of toxic protein fragments in AD might have adverse secondary effects on synapse development and function. This research will determine whether this is the case and inform new therapeutic approaches aimed at minimizing side effects.